Whole Genome Synthesis Market

The global Whole Genome Synthesis Market is valued at USD 2.41 Billion in 2024 and is projected to reach a value of USD 12.21 Billion by 2035 at a CAGR (Compound Annual Growth Rate) of 15.95% between 2025 and 2035.

Premium Insights

About 300 million people worldwide develop a rare disease, characterized as conditions that affect fewer than 1 in 2,000 people. Although genetic factors account for 80% of these diseases, finding the right genetic test and diagnosing accurately remains difficult. According to data from Europe, the United States, and Japan, finding a diagnosis takes an average of five years. Numerous studies across various age groups, nations, and symptoms of rare diseases have demonstrated cost reductions and cost-effectiveness from genetic testing for rare diseases. Among these, rapid whole genome sequencing has occurred as one of these technologies that can produce results in pediatric intensive care units quicker, more effectively, and more affordably, greatly enhancing the lives of patients and their families. Whole genome sequencing programs are driving the development of a new standard of care for some of the sickest kids globally due to their proven clinical and financial benefits.

The global whole genome synthesis market is expected to experience substantial growth in the coming years. With increased research and development activities, the demand for whole genome synthesis is expected to rise, resulting in an influx of investments in this area. The field of public health is being revolutionized by whole genome sequencing (WGS), particularly in terms of controlling and preventing of foodborne illnesses. Given its potential for changing how we detect and monitor microbial hazards in the food chain and how we assess, investigate, and manage food safety risks, WGS serves as helpful in understanding foodborne illnesses by improving routine surveillance, outbreak detection and response, and for source identification using a One Health approach. Given its benefits over earlier low-resolution typing and detection techniques, it is projected that this new technology will contribute to lowering the burden of foodborne infections.

The guidance document "Whole genome sequencing as a tool to strengthen foodborne disease surveillance and response" will be released by the World Health Organization (WHO) on July 6, 2023. It describes the capacities that must exist before WGS can be useful for foodborne disease surveillance and outbreak response, as well as the options to implement WGS and how to integrate WGS into current systems. Whole genome sequencing and whole exome sequencing are now quick and inexpensive ($689 for whole genome sequencing; one day for whole exome sequencing), and as cost and speed has decreased, the number of people who have had their genomes sequenced has increased exponentially. According to the latest edition of Science, over 30 million people have access to their detailed genomic datasets. At the same time, Ewan Birney of the European Bioinformatics Institute reports that by 2025 more than 60 million patients will have their genomes sequenced for medical purposes.

Key Highlights

• North America generated more than 48.50% of the revenue share in 2022.
• Asia Pacific will likely increase at the fastest CAGR from 2023 to 2030.
• By product and services, the software and services segment accounted for the majority of market revenue in 2022.
• By application, the personalized medicine segment had a dominant market share in 2022.
• By end user, the pharmaceutical & biotechnology segment recorded the most significant market share in 2022.

Economic Insights

To tackle implementation challenges and bring testing from centers of excellence into standard medical practice, the governments of at least 14 nations have invested exceeding US$4 billion since 2013 in establishing national genomic-medicine initiatives. Many patients with cancer and rare diseases have been tested in nations like the U.K., France, Saudi Arabia, Turkey, and Australia, where workforce and infrastructure development have been combined with genetic sequencing projects that are projected to have immediate clinical advantages. These "proof-of-principle" initiatives are bringing about change and encouraging acceptance among stakeholders in the real world while also accumulating data for wider application.

Other nations, including the United States, Denmark, Estonia, Japan, and Qatar, have invested in population-based sequencing projects with the return of results to participants, while national initiatives in the Netherlands, Switzerland, Brazil, and Finland are primarily focusing on the development of infrastructure like common standards and data-sharing policies and platforms. These initiatives may be dwarfed by the 15-year, CN¥60 Billion ($9.2 Billion) China Precision Medicine Initiative, which aims to sequence 100,000,000 genomes by 2030.

Top Market Trends

1. Growing demand for personalized medicine: Personalized medicine is a crucial area of focus in the global whole genome synthesis market. Personalized medicine involves tailoring medical treatments according to the patients unique genetic makeup, allowing for precise and effective treatment. The rising demand for personalized medicine is driven by two key factors: advances in genomic research and the increasing availability of genomic data. As genomic research continues to expand, it contributes to understanding the molecular mechanisms underlying diseases, including cancer, genetic disorders, and rare diseases. Additionally, the increasing availability of genomic data enables researchers to identify new therapeutic targets and develop more effective treatments. With an increased understanding of genetic variations, personalized medicine is becoming a reality in healthcare. Whole genome synthesis is vital in enabling personalized medicine, as it efficiently and accurately identifies disease-causing genetic mutations. This leads to quicker and more effective diagnosis and treatment of diseases, resulting in better patient outcomes. As the demand for personalized medicine grows, the global whole genome synthesis market is expected to expand significantly. The use of whole genome synthesis will likely increase as it becomes more affordable and accessible and as more patients and healthcare providers recognize its potential to improve patient care. Additionally, the growing availability of genetic data from large-scale genomic sequencing projects will drive the demand for whole genome synthesis services.

2. Advances in gene editing: Global Whole Genome Synthesis Market has witnessed significant growth in recent years, thanks to the advances in gene editing technology. Gene editing is the process of modifying DNA sequences within an organism, which can help to treat genetic disorders or even create new genetic mutations. This technology has enormous potential for the future of medicine and biotechnology. One of the most significant advances in gene editing technology is the CRISPR-Cas9 system. This system allows scientists to target specific DNA regions and make precise alterations to the genetic code. CRISPR-Cas9 has revolutionized gene editing, as it is faster, cheaper, and more effective than earlier methods. This has led to a significant increase in research in this area, particularly in developing disease treatment strategies. Another advance in gene editing technology is the ability to synthesize whole genomes. This involves using computer-based algorithms to assemble large pieces of DNA into complete chromosomes. This can give researchers a powerful tool for manipulating and studying specific genes and genetic pathways. Whole genome synthesis can have significant implications for fields such as synthetic biology and personalized medicine. Overall, the advances in gene editing technology are driving the growth of the global whole genome synthesis market. As scientists continue to develop and refine these technologies, we can expect to observe even more exciting developments in the future of medicine and biotech.

3. Growing focus on synthetic biology: Synthetic biology has gained immense prominence in the field of biotechnology in recent years. The growing emphasis on synthetic biology in the global whole genome synthesis market can be attributed to several factors. Firstly, the increasing demand for genetically modified organisms (GMOs) in various industries, such as healthcare, food and agriculture, and energy, among others, is driving the growth of synthetic biology. Secondly, advancements in the field of genomics, coupled with the development of next-generation sequencing technologies, are further fueling the demand for whole genome synthesis. Whole genome synthesis allows scientists to create entirely new biological systems and organisms with desired traits and functions. This has opened up new avenues for drug discovery, gene therapy, and bioenergy research. Thirdly, the growing need for high-quality DNA and RNA synthesis for research and diagnostic purposes is also driving the growth of synthetic biology. The ability to synthesize large quantities of DNA and RNA has significant implications for developing new drugs and therapies and diagnosing and treating genetic diseases. Moreover, increasing government investments and funding for synthetic biology research is expected to boost the growth of the global whole genome synthesis market in the coming years. Several government organizations have launched initiatives to support synthetic biology research and development, which is expected to drive the adoption of whole genome synthesis techniques.

Market Segmentation

The global Whole Genome Synthesis market can be categorized on the following: Product and Service, Application, End User, and Region. Based on Product and Service, the market can be categorized into Software and Services, Consumables, and Instruments. Furthermore, based on Application, the market can be split between Personalized Medicine, Agricultural Biotechnology, Synthetic Biology, Industrial Applications, and Others. Additionally, based on the End User, the market can be divided into Pharmaceutical & Biotechnology Companies, Diagnostic Laboratories, Academic & Research Institutes, and Contract Research Organizations (CROs). Likewise, based on Region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Based on Product and Service

Software and Services to Accommodate Maximum Market Share

The software and services segment in the global whole genome synthesis market is crucial in ensuring the efficient and effective execution of synthetic biology processes. This segment encompasses bioinformatics tools, gene synthesis services, and DNA sequencing services, enabling researchers to analyze genomic data and design synthetic genes with high accuracy and precision. The increasing demand for genomic data analysis tools and the growth of gene synthesis services are driving the markets growth. Moreover, the rising adoption of next-generation sequencing technologies and the emergence of cloud-based bioinformatics tools are also propelling the expansion of the software and services segment in the global whole genome synthesis market. Overall, this segment is expected to remain a critical growth factor for the market in the coming years.

Based on Application

Personalized Medicine to Have Foremost Market Share

Personalized medicine is an emerging segment in the global whole genome synthesis market that involves using an individuals genomic information to tailor medical treatments to their specific needs. With the advent of advanced genomic technologies, it is now possible to decode an individuals entire genome and analyze it for variations that may predispose them to certain diseases or affect their response to medications. This information can then be used to develop customized treatments that are more effective and have fewer side effects. The personalized medicine segment is projected to grow significantly in the coming years as more healthcare providers adopt genomic testing and analysis as part of their standard practice.

Based on the End User

Pharmaceutical & Biotechnology Companies to Have Major Revenue

The pharmaceutical and biotechnology companies’ segment in the global whole genome synthesis market is expected to experience significant growth in the coming years. As these companies continue to invest in research & development efforts, the demand for whole genome synthesis technology will continue to increase. Whole genome synthesis is a potent tool that enables researchers to create new organisms and identify novel therapeutic targets, helping pharmaceutical and biotechnology companies to develop innovative drugs. These companies also focus on developing personalized medicine, which relies on genomics data to identify the most effective treatments for individual patients. Thus, the pharmaceutical and biotechnology companies’ segment is expected to emerge as a critical growth driver in the global whole genome synthesis market.

Based on Region

North America to Lead Global Sales

The North American whole genome synthesis market has major growth due to the increasing adoption of synthetic biology and genetic engineering. The demand for whole genome synthesis is fueled by the growing number of genome-related research projects, which require high-quality and accurate synthetic DNA fragments. The rise of gene editing technologies such as CRISPR/Cas9 also contributes to the markets growth. In addition, North America has a well-established healthcare infrastructure and advanced research facilities, which attract significant investments in synthetic biology. The presence of key market players such as Twist Bioscience, GenScript Biotech, and Integrated DNA Technologies propel market growth.

Moreover, the United States holds the largest market share due to extensive funding for synthetic biology research, well-established research infrastructure, and increasing demand for personalized medicine. However, the high cost of whole genome synthesis and the lack of skilled professionals who can effectively use the technology may hinder market growth. Nevertheless, due to the growing demand for synthetic genetic material, the market is expected to continue its growth trajectory.

The Asia Pacific whole genome synthesis market is projected to grow significantly in the forecast period. Increasing demand for personalized medicine, advancements in genome editing technologies, and an increase in the prevalence of genetic diseases are driving market growth. The region is also witnessing increased government initiatives to promote genomics research. Additionally, the growing demand for synthetic biology research and the increasing number of contract research organizations (CROs) offering genomic services provide a good platform for market growth. China is estimated to be the largest market due to the presence of major market players and government initiatives promoting genome research. The market players focus on partnerships and collaborations to enhance their product portfolios and maintain their market presence.

Competitive Landscape

The global whole genome synthesis market is highly competitive, with the presence of several established players as well as newer entrants. Companies focus on various growth strategies such as product launches, partnerships, collaborations, and acquisitions to strengthen their market position. Moreover, the rise in the number of alliances and partnerships is expected to facilitate technological advancements and the development of new products and services in the market. The increasing demand for personalized medicine and oncology research is expected to drive the growth of the global whole genome synthesis market in the coming years. The availability of advanced technologies and the increasing adoption of synthetic biology and genetic engineering is also anticipated to propel the markets growth. However, the high cost of whole genome synthesis and the need for more awareness and skilled personnel in developing countries may hinder market growth.

The key players in the global Whole Genome Synthesis market include - Twist Bioscience (U.S.) among others.

Recent Market Developments

• Feb 2023: Twist Bioscience has announced technology early access for its enhanced whole genome sequencing solution at AGBT. At the Advances in Genome Biology and Technology (AGBT) 2023 General Meeting in Hollywood, Florida, Twist Bioscience Corporation, a company that helps customers succeed by providing high-quality synthetic DNA using its silicon platform, today announced technology early access of the Twist enhanced Whole Genome Sequencing (eWGS) solution focused on non-human genomics applications.
• Feb 2022: Integrated DNA Technologies (IDT) introduces a new method to quicken the research of homology-directed repair in genome editing. With the introduction of Alt-R HDR Donor Blocks, a better way to raise homology-directed repair (HDR) rates in large fragment knock-in experiments, global genomics solutions provider Integrated DNA Technologies (IDT) enables researchers to fuel scientific advancements in gene editing. The advanced chemical modifications used in IDTs Alt-R HDR Donor Blocks increase the HDR rates of major genomic insertions and alterations while significantly lowering the incidence of non-homologous (blunt) integration of the donor sequence.

Segmentation of the Global Whole Genome Synthesis Market